FDA Adverse Event Other Summary report: N

ABACUS TPN CALCULATING SOFTWARE

MDR report key: 909814 · Received September 7, 2007

Report

Report Number
1419106-2007-00009
Event Type
Other
Date Received
September 7, 2007
Date of Event
August 11, 2007
Report Date
August 11, 2007
Manufacturer
BAXA CORPORATION
Product Code
LNX
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NV, US
Reporter Occupation
PHARMACIST

Narratives

Additional Manufacturer Narrative · 1

A REVIEW OF THE ORDER FORM AND THE DATABASE REVEALED THAT THE SOFTWARE FUNCTIONED AS DESIGNED. THE SAFETY FEATURES (INGREDIENT VOLUME WARNINGS) RESIDENT IN THE SOFTWARE WERE NOT PROPERLY EMPLOYED. THE VERIFICATION LABEL ALONG WITH THE ASSOCIATED DOCUMENTATION THAT IS PRODUCED WITH THE ORDER OF THE TPN BAG CLEARLY INDICATE THE VOLUME OF RANITIDINE IN THE TPN SOLUTION; PHARMACIST AND PHYSICIAN VERIFICATION OF THE TPN BAG FAILED TO IDENTIFY THE HIGHER -THAN-DESIRED ORDERED AMOUNT OF RANITIDINE. A REVIEW OF THE PRODUCT HAZARD ANALYSIS (PHA) AND CUSTOMER COMPLAINT DATA FOR THIS PRODUCT WAS CONDUCTED, AND IT WAS DETERMINED THAT THIS ISSUE NOT OCCURRING WITH GREATER FREQUENCY OR SEVERITY THAN IS EXPECTED FOR THE DEVICE, AS DOCUMENTED IN THE PHA.

Description of Event or Problem · 1

IN 2007, BAXA WAS NOTIFIED OF AN INCIDENT THAT RESULTED IN A PATIENT REQUIRING ADDITIONAL MONITORING FOR POTENTIAL SIDE EFFECTS FROM AN OVER DOSE OF RANITIDINE (ZANTAC). THE CUSTOMER REPORTED THAT WHILE USING THE ABACUS TPN CALCULATING SOFTWARE FOR CREATING A TPN SOLUTION, THAT A PATIENT WAS INFUSED WITH A TPN SOLUTION THAT CONTAINED A HIGHER-THAN-DESIRED VOLUME OF RANITIDINE (ZANTAC) FOR THIS PARTICULAR PATIENT. THE DOSE OF RANITIDINE (ZANTAC), RATHER THAN BEING 24MG/DAY WAS ENTERED AS 24MG/KG, APPROXIMATELY 7.6 TIMES THE ORIGINAL ORDERED AMOUNT. THE CUSTOMER REPORTED THAT NO ADVERSE EVENT RESULTED FROM THE OVER-DELIVERY OF RANITIDINE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ABACUS TPN CALCULATING SOFTWARE ABACUS SINGLE WORK STATION LNX BAXA CORPORATION 8300-0046 NA

Patients

Seq Age Sex Outcome Treatment
1 YR Required Intervention